K
Kendelle J. Murphy
Researcher at Garvan Institute of Medical Research
Publications - 30
Citations - 1058
Kendelle J. Murphy is an academic researcher from Garvan Institute of Medical Research. The author has contributed to research in topics: Cancer & Metastasis. The author has an hindex of 11, co-authored 23 publications receiving 569 citations. Previous affiliations of Kendelle J. Murphy include University of New South Wales.
Papers
More filters
Journal ArticleDOI
Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.
Sunny Z. Wu,Sunny Z. Wu,Daniel L. Roden,Daniel L. Roden,Chenfei Wang,Holly Holliday,Holly Holliday,Kate Harvey,Aurélie Cazet,Aurélie Cazet,Kendelle J. Murphy,Kendelle J. Murphy,Brooke A. Pereira,Brooke A. Pereira,Ghamdan Al-Eryani,Ghamdan Al-Eryani,Nenad Bartonicek,Nenad Bartonicek,Rui Hou,James R. Torpy,James R. Torpy,Simon Junankar,Simon Junankar,Chia Ling Chan,Chuan En Lam,Mun N. Hui,Laurence Gluch,Jane Beith,Andrew Parker,Elizabeth Robbins,Davendra Segara,Cindy Mak,Caroline Cooper,Caroline Cooper,Sanjay Warrier,Alistair R. R. Forrest,Joseph E. Powell,Joseph E. Powell,Sandra A O'Toole,Sandra A O'Toole,Thomas R. Cox,Thomas R. Cox,Paul Timpson,Paul Timpson,Elgene Lim,Elgene Lim,Elgene Lim,X. Shirley Liu,Alexander Swarbrick,Alexander Swarbrick +49 more
TL;DR: Investigation of gene signatures from inflammatory‐CAFs and differentiated‐PVL cells in independent TNBC patient cohorts revealed strong associations with cytotoxic T‐cell dysfunction and exclusion, respectively, presenting promising candidates for new therapeutic strategies in the treatment of TNBCs.
Journal ArticleDOI
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan
Claire Vennin,Claire Vennin,Claire Vennin,Pauline Mélénec,Pauline Mélénec,Romain Rouet,Romain Rouet,Max Nobis,Max Nobis,Aurélie Cazet,Aurélie Cazet,Kendelle J. Murphy,Kendelle J. Murphy,David Herrmann,David Herrmann,Daniel A Reed,Daniel A Reed,Morghan C. Lucas,Morghan C. Lucas,Sean C. Warren,Sean C. Warren,Zehra Elgundi,Mark Pinese,Mark Pinese,Gabriella Kalna,Daniel L. Roden,Daniel L. Roden,Monisha Samuel,Anaiis Zaratzian,Shane T. Grey,Shane T. Grey,Andrew M. Da Silva,Wilfred Leung,Wilfred Leung,Wilfred Leung,Australian Pancreatic Genome Initiative,Suresh Mathivanan,Yingxiao Wang,Anthony W Braithwaite,Anthony W Braithwaite,Daniel Christ,Daniel Christ,Aleš Benda,Ashleigh Parkin,Ashleigh Parkin,Phoebe A. Phillips,John M. Whitelock,Anthony J. Gill,Owen J. Sansom,David R. Croucher,David R. Croucher,Benjamin L. Parker,Marina Pajic,Marina Pajic,Jennifer P. Morton,Thomas R. Cox,Thomas R. Cox,Paul Timpson,Paul Timpson +58 more
TL;DR: It is revealed that depleting perlecan in the stroma combined with chemotherapy prolongs mouse survival, supporting it as a potential target for anti-stromal therapies in pancreatic cancer and identifying perle can as a mediator of the pro-metastatic environment.
Journal ArticleDOI
Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Claire Vennin,Kendelle J. Murphy,Kendelle J. Murphy,Jennifer P. Morton,Thomas R. Cox,Thomas R. Cox,Marina Pajic,Marina Pajic,Paul Timpson,Paul Timpson +9 more
TL;DR: Relationships between the pancreatic tumor extracellular matrix, the vasculature, the immune system, and metabolism, are described and the implications for the development of stromal compartment-specific therapies are discussed.
Journal ArticleDOI
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
Angela Chou,Danielle Froio,Adnan Nagrial,Adnan Nagrial,Ashleigh Parkin,Kendelle J. Murphy,Venessa T. Chin,Dalia Wohl,Angela Steinmann,Rhys Stark,Alison Drury,Stacey N. Walters,Claire Vennin,Andrew Burgess,Andrew Burgess,Mark Pinese,Lorraine A. Chantrill,Lorraine A. Chantrill,Mark J. Cowley,Timothy J. Molloy,Nicola Waddell,Amber L. Johns,Sean M. Grimmond,David K. Chang,Andrew V. Biankin,Owen J. Sansom,Jennifer P. Morton,Shane T. Grey,Shane T. Grey,Thomas R. Cox,John Turchini,Jaswinder S. Samra,Stephen Clarke,Paul Timpson,Paul Timpson,Anthony J. Gill,Marina Pajic,Marina Pajic +37 more
TL;DR: Subtype-specific in vivo efficacy of PD-0332991-based therapy was for the first time observed at multiple stages of PDA progression: primary tumour growth, recurrence (second-line therapy) and metastatic setting and may potentially be guided by a simple biomarker (RB protein).
Journal ArticleDOI
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.
James R.W. Conway,Sean C. Warren,David Herrmann,David Herrmann,Kendelle J. Murphy,Aurélie Cazet,Claire Vennin,Robert F. Shearer,Monica J. Killen,Astrid Magenau,Astrid Magenau,Pauline Mélénec,Mark Pinese,Mark Pinese,Max Nobis,Anaiis Zaratzian,Alice Boulghourjian,Andrew M. Da Silva,Gonzalo del Monte-Nieto,Gonzalo del Monte-Nieto,Arne S.A. Adam,Richard P. Harvey,Richard P. Harvey,Jody J. Haigh,Yingxiao Wang,David R. Croucher,David R. Croucher,David R. Croucher,Owen J. Sansom,Marina Pajic,Marina Pajic,C. Elizabeth Caldon,C. Elizabeth Caldon,Jennifer P. Morton,Paul Timpson,Paul Timpson +35 more
TL;DR: Application of advanced intravital imaging facilitates dynamic monitoring of pathway activity upon therapeutic inhibition and demonstrates an improved drug response to a combination therapy using the dual mTORC1/2 inhibitor AZD2014 with the hypoxia-activated pro-drug TH-302.